Eagle Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Eagle Pharmaceuticals's earnings have been declining at an average annual rate of -47.6%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 5.4% per year. Eagle Pharmaceuticals's return on equity is 4.7%, and it has net margins of 4.6%.
Key information
-47.6%
Earnings growth rate
-48.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -5.4% |
| Return on equity | 4.7% |
| Net Margin | 4.6% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
Sep 21
Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Jul 13Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly
Jun 21These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Oct 27Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia
Oct 12Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose
Sep 27Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court
Aug 18Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be
Aug 15Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M
Aug 09These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Jul 06Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price
Apr 29Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?
Dec 16Revenue & Expenses Breakdown
How Eagle Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 258 | 12 | 103 | 36 |
| 31 Mar 23 | 267 | -3 | 93 | 37 |
| 31 Dec 22 | 317 | 36 | 87 | 34 |
| 30 Sep 22 | 298 | 21 | 82 | 31 |
| 30 Jun 22 | 272 | 23 | 79 | 45 |
| 31 Mar 22 | 246 | 36 | 78 | 43 |
| 31 Dec 21 | 172 | -9 | 75 | 51 |
| 30 Sep 21 | 179 | 6 | 76 | 57 |
| 30 Jun 21 | 189 | 18 | 75 | 38 |
| 31 Mar 21 | 183 | 14 | 76 | 36 |
| 31 Dec 20 | 188 | 12 | 79 | 31 |
| 30 Sep 20 | 186 | 5 | 80 | 33 |
| 30 Jun 20 | 177 | -5 | 81 | 38 |
| 31 Mar 20 | 192 | 2 | 80 | 40 |
| 31 Dec 19 | 196 | 14 | 76 | 37 |
| 30 Sep 19 | 204 | 26 | 69 | 31 |
| 30 Jun 19 | 214 | 42 | 65 | 27 |
| 31 Mar 19 | 216 | 38 | 63 | 33 |
| 31 Dec 18 | 213 | 32 | 61 | 44 |
| 30 Sep 18 | 204 | 28 | 58 | 48 |
| 30 Jun 18 | 216 | 30 | 61 | 51 |
| 31 Mar 18 | 207 | 32 | 68 | 42 |
| 31 Dec 17 | 237 | 52 | 71 | 33 |
| 30 Sep 17 | 271 | 100 | 77 | 38 |
| 30 Jun 17 | 246 | 97 | 71 | 33 |
| 31 Mar 17 | 237 | 105 | 60 | 30 |
| 31 Dec 16 | 189 | 81 | 53 | 28 |
| 30 Sep 16 | 127 | 25 | 40 | 22 |
| 30 Jun 16 | 94 | 3 | 35 | 25 |
| 31 Mar 16 | 60 | -18 | 28 | 27 |
| 31 Dec 15 | 66 | 3 | 20 | 28 |
| 30 Sep 15 | 54 | -4 | 19 | 23 |
| 30 Jun 15 | 51 | -3 | 17 | 22 |
| 31 Mar 15 | 51 | 2 | 14 | 21 |
| 31 Dec 14 | 20 | -21 | 12 | 19 |
| 30 Sep 14 | 19 | -20 | 9 | 17 |
| 30 Jun 14 | 17 | -11 | 4 | 14 |
| 31 Mar 14 | 20 | -9 | 3 | 11 |
| 31 Dec 13 | 18 | -11 | 4 | 10 |
Quality Earnings: EGRX has high quality earnings.
Growing Profit Margin: EGRX's current net profit margins (4.6%) are lower than last year (8.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if EGRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: EGRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: EGRX had negative earnings growth (-47.6%) over the past year, making it difficult to compare to the Biotechs industry average (0.5%).
Return on Equity
High ROE: EGRX's Return on Equity (4.7%) is considered low.